Cartesian Therapeutics, Inc. RNAC R2KPHARMA
Company Overview
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Why Investors Should Care
Generates a return on equity of 103.2%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $2.80M (-92.8% YoY); net profit $-130.30M.
- Trailing 12 Months Year-on-year growth — revenue -92.8%, earnings -8.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.83% |
| 1 Year: | -92.81% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -8.00% |
Stock Price Performance
| 1 Year: | -47.22% |
| 6 Months: | -8.44% |
| 3 Months: | -20.67% |
| 1 Month: | -18.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)32.57 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 103.2%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -0.8% CAGR over 5 years.
- Trading 47.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RNAC Cartesian Therapeutics, Inc. R2KPHARMA | 6.18 | -1.07 | $186.98M | 0.00% | -30.80% | 103.22% | -0.83% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 137.00K | 26.00K | 27.00K | 17.00K | 0 | 0 | 0 | 903.00K | 10.00K | 13.00K | 0 | 6.65M | 0 | 0 | 4.65M | 11.05M | 19.66M | 24.43M | 34.00M | 39.27M | 20.71M | 5.94M | 5.25M | 6.55M | 5.84M | 33.27M | 0 | 400.00K | 0 | 0 | 0 | 0 |
| Operating Income | - | -6.32M | -6.07M | - | -6.94M | -6.40M | -7.47M | - | -14.78M | -15.87M | -13.85M | - | -15.81M | -18.77M | -15.94M | - | -11.86M | -16.23M | -11.79M | - | -18.82M | -16.37M | -13.73M | -7.16M | 452.00K | -1.97M | 10.77M | 13.86M | -1.60M | -18.38M | -18.64M | -13.06M | -13.35M | 13.76M | -17.57M | -21.89M | -21.81M | -21.07M | -26.50M | -29.16M |
| Net Income | -5.73M | -6.87M | -5.72M | -6.85M | -7.48M | -6.92M | -7.73M | -14.08M | -15.13M | -15.97M | -14.68M | -19.54M | -15.89M | -18.80M | -16.00M | -14.65M | -12.07M | -16.39M | -11.99M | -14.89M | -19.62M | -24.08M | -9.73M | -24.60M | 4.57M | -17.89M | 28.78M | 8.60M | -7.89M | -21.66M | -11.39M | -9.00M | -56.82M | 13.84M | -24.18M | -17.71M | 15.89M | -35.90M | -39.18M | 15.77M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.25 | -0.09 | -0.22 | 0.00 | -0.16 | 0.08 | 0.06 | -0.05 | -4.24 | -2.23 | -1.74 | -10.50 | 0.54 | -1.13 | -0.68 | 0.50 | -1.38 | -1.46 | 0.46 |
| R&D Expense | - | 5.31M | 5.48M | - | 6.65M | 6.00M | 6.02M | - | 11.04M | 10.99M | 9.50M | - | 11.14M | 14.41M | 11.88M | - | 7.35M | 12.13M | 8.10M | - | 14.72M | 10.73M | 13.96M | 13.00M | 14.46M | 20.95M | 17.69M | 19.18M | 16.54M | 18.62M | 17.78M | 13.00M | 9.74M | 12.66M | 11.40M | 14.67M | 14.87M | 13.80M | 19.46M | 20.43M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.04M | 6.01M | 8.08M | 207.00K | 903.00K | 6.68M | 16.60M | - | 110.78M | 26.00M | 38.91M | 2.80M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 96.24M | 111.71M | 75.23M | 89.50M |
| Operating Income | -15.40M | -25.30M | -34.67M | -63.78M | -65.02M | -52.45M | -56.82M | - | 14.54M | -85.71M | -36.32M | -86.70M |
| EBITDA | - | - | - | - | - | - | - | - | 39.09M | -235.03M | -75.99M | -83.75M |
| Interest Expense | - | - | - | - | - | - | - | 2.84M | 3.03M | 2.83M | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | 34.77M | -238.71M | -77.14M | -139.50M |
| Tax Provision | - | - | - | - | - | - | - | - | -609.00K | -19.00M | 287.00K | -9.19M |
| Net Income | -12.88M | -25.17M | -36.21M | -65.32M | -65.34M | -55.35M | -68.88M | - | 35.38M | -219.71M | -77.42M | -130.30M |
| Diluted EPS | - | - | - | - | - | -1.22 | -0.68 | - | 3.00 | -49.76 | -4.49 | -5.02 |
| R&D Expense | 10.49M | 22.98M | 29.70M | 45.16M | 47.69M | 42.74M | 54.51M | 68.74M | 72.38M | 71.26M | 45.10M | 58.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Jan 2018 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 42.82M | 89.30M | 101.10M | 101.10M | 44.48M | 99.57M | 165.44M | 159.88M | 165.89M | 305.05M | 435.02M | 296.41M |
| Total Equity | -69.46M | -87.75M | -116.49M | 54.96M | 51.81M | 53.64M | -5.42M | 8.40M | -18.01M | 22.52M | 93.83M | -440.18M | -6.80M | -126.24M |
| Cash & Equivalents | 8.06M | 16.59M | 32.34M | 58.66M | 70.62M | - | 37.40M | 89.89M | 138.69M | 114.06M | 106.44M | 76.91M | 212.61M | 125.14M |
| Total Liabilities | - | - | 21.84M | 34.34M | 49.29M | 47.46M | 49.90M | 91.17M | 183.44M | 137.36M | 72.06M | 444.68M | 441.82M | 422.65M |
| Current Liabilities | - | - | 7.29M | 13.71M | 10.97M | 10.97M | 35.14M | 34.94M | 81.55M | 72.25M | 25.08M | 68.21M | 22.98M | 14.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -22.46M | -19.76M | -52.03M | -59.16M | -51.44M | 34.88M | -60.38M | -31.63M | -51.16M | -23.67M | -73.94M |
| Investing Cash Flow | - | -4.68M | -22.10M | -2.10M | 25.27M | 229.00K | -741.00K | -17.14M | -15.00M | 34.61M | -8.74M | -5.45M |
| Financing Cash Flow | - | 43.91M | 67.66M | 66.02M | 697.00K | 105.04M | 14.43M | 52.90M | 39.22M | -13.14M | 168.43M | -8.05M |
| Capital Expenditure | -227.00K | -1.16M | -586.00K | -733.00K | -884.00K | -47.00K | -815.00K | -1.08M | -1.20M | -206.00K | -9.09M | -5.45M |
| Free Cash Flow | - | -23.63M | -20.34M | -52.76M | -60.05M | -51.48M | 34.07M | -61.47M | -32.83M | -51.37M | -32.77M | -79.39M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -506.5% | -421.0% | -428.9% | -30,813.5% | -7,200.7% | -785.6% | -342.4% | - | 13.1% | -329.6% | -93.3% | -3,099.9% |
| Net Margin % | -423.7% | -418.8% | -448.0% | -31,556.0% | -7,235.4% | -829.0% | -415.0% | - | 31.9% | -844.9% | -199.0% | -4,658.6% |
| ROE % | 14.7% | 21.6% | -65.9% | -126.1% | 1,205.9% | -659.2% | 382.5% | - | 37.7% | 49.9% | 1,138.3% | 103.2% |
| ROCE % | - | -71.2% | -45.9% | -70.8% | -696.3% | -81.2% | -67.7% | - | 10.3% | -36.2% | -8.8% | -30.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Squarepoint Ops LLC | 7.45% | 2.25M | $15.91M |
| 2 | Blackrock Inc. | 2.71% | 819.24K | $5.78M |
| 3 | 683 Capital Management LLC | 2.15% | 650.00K | $4.59M |
| 4 | Vanguard Capital Management LLC | 1.84% | 555.82K | $3.92M |
| 5 | FMR, LLC | 1.22% | 368.43K | $2.60M |
| 6 | Geode Capital Management, LLC | 1.18% | 356.52K | $2.52M |
| 7 | AQR Capital Management, LLC | 1.18% | 356.46K | $2.51M |
| 8 | Millennium Management Llc | 1.02% | 309.89K | $2.19M |
| 9 | Two Sigma Investments, LP | 0.98% | 296.29K | $2.09M |
| 10 | State Street Corporation | 0.82% | 249.21K | $1.76M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNAC
RNAC Feb 2027 12.500 call (RNAC270219C00012500) Stock Historical Prices & Data - Yahoo Finance - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFBVR2JqNGxjMUlWR0R6Q3JUb3JMRDJLRWFvQVU4NmNXNUllOF9SMFVZbVAzSE5sa3R5NktzRmVYaHNQeGtjcnNveFYyQWtlMU1IZmdORGQ2dW9OaGVzaXk0SUsyaXZtb3lBOXMwV1YyVWE?oc=5" target="_blank">RNAC Feb 2027 12…
RNAC Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1iVVV1Z1A2NjZmeWJPMTBIYkNoU1QxXzEzUk1jczJKcVRwbmt5SXVRMktnSGZQaXBsd2MteFZRTkhMMF8xRWE1Z0hlblBPWC1NZmVFZGh2N1hHTGl0d2Voa3V1N25PRHAxamNKZlg0OUpEQzNnQTl5cjV3?oc=5" target="_blank">RNA…
APP,RCAT,CCC,OPTU,INOD,MRKR,RNAC,OKLO,ARDX,AJG | Stock Prices | Quote Comparison - Yahoo Finance - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQTnk3b1dEYUlCemJkeTZLbTNEYThrWUxkZ3FiMXlENU9rQVhiM1lQU0tpQk5FQnNVRklWcXV0OVk1eFJKdmRYOXJFOTUyVkE2M29Ncmx4bnlka29YUWJndTZtNjFOWF9oeC1JaEdhS3B6S2lnczlMQTM3OU16T2QxaThrOW9vWE1va3pF?o…
Cartesian Therapeutics Stock: A Phase 3 mRNA CAR-T Bet (NASDAQ:RNAC) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPcUV0Y1dmZGpuME1rNVVMaFRqOHhvTVBrWlNCbVV6cTNIZ09ta25YVUFOeTRXTDl1cU9OaFhpNXVfVTkyU2oybjlEQmgwU2RzZjhjOTc3UTJqU3BtOHZCVW5qNWQwY2JsN1VGSUwwMnU3MEd5VWNHUDlNNXFFdWF5akJxMHQxbUg2NzgtZW…
The Technical Signals Behind (RNAC) That Institutions Follow - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQNm9ubE82QktVb3JTazhOaXpFTkVpMm1zd0NsVmZ6MW1JMk1TTDR2NXEwaVVfalhuNzgyU043V3BpTGdyXzhJZFFfVFFWel9KQm5YbHh5aHYtWl9Kd2gtQXJZMk5FaDYzcEdNdTZoTXZoZlU1Rmk2Qnh6ek9rcWVkTUhidXA2SnlWMnFic0…
H.C. Wainwright reiterates Cartesian Therapeutics stock rating at buy - Investing.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNX2tEeU1Hb01JSU9mbU9USm9wdkhneUpYeG5BSTQwNk4zMTVadTJnUVF4anFnU05heDROQ2NEMnJPOHJUMUVhMThybjRZN05PYzBMYUlZOHN2RVZqNWlBYWNDVFBKOEttbFlFNU5scXp6MHlIOHZoSDVOMVRuNmczOTdFa0lIN3dMUVc4ME…
RNAC — Frequently Asked Questions
What is the current share price of Cartesian Therapeutics, Inc. (RNAC)?
As of 2026-10-23 16:27 PDT, Cartesian Therapeutics, Inc. (RNAC) trades at $6.18 on NasdaqGM. Its 52-week range is $5.84 to $11.71.
What is the market capitalisation of RNAC?
Cartesian Therapeutics, Inc. (RNAC) has a market capitalisation of $186.98M on NasdaqGM.
What is the P/E ratio of RNAC?
RNAC trades at a trailing price-to-earnings (P/E) ratio of -1.07. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -1.93.
What is the return on equity (ROE) of RNAC?
RNAC has a return on equity (ROE) of 103.22%. Its return on capital employed (ROCE) is -30.80%.
Is RNAC a good stock to buy?
This page provides a data-driven analysis of Cartesian Therapeutics, Inc. (RNAC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.